Article

ERK Inhibitor ASN007 Effectively Overcomes Acquired Resistance to EGFR Inhibitor in Non-small Cell Lung Cancer

2021-02-23

Abstract excerpt

<title>Abstract</title> <p>The emergence of acquired resistance limits the long-term efficacy of EGFR tyrosine kinase inhibitors (EGFR-TKIs). Thus, development of effective strategies to overcome resistance to EGFR-TKI is urgently needed. Multiple mechanisms to reactivate ERK signaling have been successfully demonstrated in acquired resistance models. We found that in EGFR mutant non-small cell lung cancer (NSCLC...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 0a0b5926-a129-5e88-bfca-ddd5e95efec5
DOI: 10.21203/rs.3.rs-249758/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

ERK Inhibitor ASN007 Effectively Overcomes Acquired Resistance to EGFR Inhibitor in Non-small Cell Lung CancerDOI 10.21203/rs.3.rs-249758/v1Read

ERK inhibitor ASN007 effectively overcomes acquired resistance to EGFR inhibitor in non-small cell lung cancer.Semantic proximity Read

ASN007 is a selective ERK1/2 inhibitor with preferential activity against RAS-and RAF-mutant tumors.Semantic proximity Read

ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.Semantic proximity Read

Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib.Semantic proximity Read

Acquired resistance to AZD9291 as an upfront treatment is dependent on ERK signaling in a preclinical model.Semantic proximity Read

Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance.Semantic proximity Read

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.Semantic proximity Read

SH003 enhances the anti-cancer effects of Dabrafenib on lung cancer harboring BRAF G469A mutation by inhibiting the MAPK signaling pathwaySemantic proximity Read

ASTX029, a Novel Dual-mechanism ERK Inhibitor, Modulates Both the Phosphorylation and Catalytic Activity of ERKSemantic proximity Read

MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor-mutant lung cancers.Semantic proximity Read

Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.Semantic proximity Read

ERK Mutations and Amplification Confer Resistance to ERK-Inhibitor Therapy.Semantic proximity Read